Loading company
Just reported
Q3 2026 results
From Puma Biotechnology's results release of November 5, 2026; its quarterly report has since been filed.
Revenue
Actual
$55.1M
+1.1% y/y
-2.6% q/qGuided
$57.5M
midpoint
Below guide-4.3%EPS, GAAP
Actual
$0.11
-35% y/y
-31% q/qGuided
—
No guide given
Operating income, GAAP
Actual
$5.3M
-45% y/y
-30% q/qGuided
—
No guide given
Company outlook
Full year 2026
- Revenue$224M – $227M-1.3% y/y First given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Puma Biotechnology is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Biotechnology
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.$47.6BA+
EXELExelixis, Inc.$16.8BA+
JAZZJazz Pharmaceuticals plc$15.5BA
TECHBIO-Techne Corp$11.4BA+
HALOHalozyme Therapeutics, Inc.$11.4BA+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher CorporationOct 21, 2026CBGraded C, now B
MCKMckesson CorporationNov 4, 2026BAGraded B, now A
CVSCVS Health CorpNov 4, 2026BAGraded B, now A
EWEdwards Lifesciences CorporationNov 4, 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.Oct 28, 2026CAGraded C, now A
Built from Puma Biotechnology, Inc.’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
